Citations

Clear

3138 citation(s) found for "Smith, AM".

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, William J. , Anderson, Benjamin O. , Abraham, Jame , Aft, Rebecca , Allison, Kimberly H. , Blair, Sarah L. , Burstein, Harold J. , Dang, Chau T. , Goldstein, Lori J. , Isakoff, Steven J. , Lyons, Janice A., Matro, Jennifer M. , Moran, Meena S. , Patel, Sameer A. , Pierce, Lori J. , Sitapati, Amy M. , Smith, Mary Lou , Stringer-Reasor, Erica , Telli, Melinda L. , Burns, Jennifer L. , Agnese, Doreen Marie , Elias, Anthony , Giordano, Sharon H. , Goetz, Matthew P. , Krishnamurthy, Jairam , Marcom, Paul Kelly , Mayer, Ingrid A. , Mortimer, Joanne , O'Regan, Ruth M , Rugo, Hope S. , Smith, Karen L. , Soliman, Hatem Hussein , Ward, John Headley , Young, Jessica S. , Kumar, Rashmi , Telli, Melinda L

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 7, 2020 | Volume: 18 | Issue: 4 | Pages: 452-478

10.6004/jnccn.2020.0016 | PMID 32259783 Get It

Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.
ENGINE: A Phase III Randomized Placebo Controlled Study of Enzastaurin/R-CHOP as Frontline Therapy in High-Risk Diffuse Large B-Cell Lymphoma Patients with the Genomic Biomarker DGM1
Nowakowski, Grzegorz S. , Zhu, Jun , Zhang, Qingyuan , Sun, Xiuhua , Maly, Joseph, Rizvi, Syed , Song, Yongping , Jing, Hongmei , Cao, Junning , Zhang, Lei , Han, Isabel, Sun, Joan, Jivani, Manoj A., Liu, Young, Heineman, Thomas C. , Smith, Stephen D. , Brody, Joshua , Song, Yuqin , Lansigan, Frederick , Lue, Jennifer Kimberly , Luo, Wen , Li, Ling

Mayo Clinic

Future Oncology | April 6, 2020 | Volume: 16 | Issue: 15 | Pages: 991-999

10.2217/fon-2020-0176 | PMID 32250167 Get It

Coagulation test changes associated with acute normovolemic hemodilution in cardiac surgery
Nuttall, Gregory A. , Mauermann, William J., Schroeder, Darrell R. , Scott, Phillip D., Smith, Mark M , Schroeder, Darrell , Smith, Bradford B. , Smith, Mark M.

Mayo Clinic

Journal of Cardiac Surgery | April 5, 2020 | Volume: 35 | Issue: 5 | Pages: 1043-1050

10.1111/jocs.14532 | PMID 32248625 Get It

Combined influence of inspiratory loading and locomotor subsystolic cuff inflation on cardiovascular responses during submaximal exercise
Smith, Joshua R. , Bruhn, Eric J., Berg, Jessica, Nur, Amran A., Villarraga, Nicolas , Olson, Thomas P. , Berg, Jessica D, Smith, Joshua R

Mayo Clinic

Journal of Applied Physiology | April 2, 2020 | Volume: 128 | Issue: 5 | Pages: 1338-1345

10.1152/japplphysiol.00781.2019 | PMID 32240016 Get It

Reflexes arising from the respiratory and locomotor muscles influence cardiovascular regulation during exercise. However, it is unclear how the respiratory and locomotor muscle reflexes interact when simultaneously stimulated. Herein, we demonstrate that stimulation of the respiratory and locomotor muscle reflexes yielded additive cardiovascular responses during submaximal exercise.
Acute Kidney Injury Patterns Following Transplantation of Steatotic Liver Allografts
Jadlowiec, Caroline C. , Neville, Matthew R., Abdelwahab, Dina, Reddy, Kunam S. , Moss, Adyr A. , Aqel, Bashar , Taner, Timuçin , Jadlowiec, Caroline , Neville, Matthew, Mao, Shennen, Aqel, Bashar A. , Taner, Timucin , Smith, Maxwell L. , Mao, Shennen A.

Mayo Clinic

Journal of Clinical Medicine | April 2, 2020 | Volume: 9 | Issue: 4 | Pages: 954

10.3390/jcm9040954 | PMID 32235545 Get It

Background: Steatotic grafts are increasingly being used for liver transplant (LT); however, the impact of graft steatosis on renal function has not been well described. Methods: A total of 511 allografts from Mayo Clinic Arizona and Minnesota were assessed. We evaluated post-LT acute kidney injury (AKI) patterns, perioperative variables and one-year outcomes for patients receiving moderately steatotic allografts (>30% macrovesicular steatosis, n = 40) and compared them to non-steatotic graft recipients. Results: Post-LT AKI occurred in 52.5% of steatotic graft recipients versus 16.7% in non-steatotic recipients (p < 0.001). Ten percent of steatotic graft recipients required new dialysis post-LT (p = 0.003). At five years, there were no differences for AKI vs. no AKI patient survival (HR 0.95, 95% CI 0.08–10.6, p = 0.95) or allograft survival (HR 1.73, 95% CI 0.23–13.23, p = 0.59) for those using steatotic grafts. Lipopeliosis on biopsy was common in those who developed AKI (61.0% vs. 31.6%, p = 0.04), particularly when the Model for End-Stage Liver Disease (MELD) was ≥20 (88.9%; p = 0.04). Lipopeliosis was a predictor of post-LT AKI (OR 6.0, 95% CI 1.1–34.6, p = 0.04). Conclusion: One-year outcomes for moderately steatotic grafts are satisfactory; however, a higher percentage of post-LT AKI and initiation of dialysis can be expected. Presence of lipopeliosis on biopsy appears to be predictive of post-LT AKI.
GLILD Revisited
Larsen, Brandon T. , Tazelaar, Henry D. , Yi, Eunhee S. , Ryu, Jay H. , Ryu, Jay H , Smith, Maxwell L. , Tazelaar, Henry D. , Churg, Andrew

Mayo Clinic

American Journal of Surgical Pathology | April 1, 2020 | Volume: 44 | Issue: 8 | Pages: 1073-1081

10.1097/pas.0000000000001479 | PMID 32235152 Get It

Common variable immunodeficiency (CVID) and selective immunoglobulin A deficiency (IgAD) often cause chronic lung disease, but the pulmonary pathologic features of these systemic diseases are poorly recognized by pathologists. It has been claimed that CVID cases show a characteristic combination of noncaseating granulomas-lymphoid proliferations termed granulomatous-lymphocytic interstitial lung disease (GLILD). We present 34 surgical lung biopsy cases of CVID and 4 of IgAD. Noncaseating granulomas were seen in 23/34 (68%) CVID and 2/4 (50%) IgAD cases. A statistically identical pattern of benign lymphoid proliferation was found in CVID and IgAD whether or not granulomas were present. Organizing pneumonia, sometimes considered a part of GLILD, was seen in 25/34 (74%) CVID and 2/4 (50%) IgAD cases and did not correlate with the presence of granulomas. On follow-up, 3 CVID patients died (only 1 of pulmonary disease), while 21 others are alive at 1 to 300 months with no difference by presence or absence of granulomas. Three IgAD patients with follow-up are alive. We conclude that CVID and IgAD are indistinguishable in surgical lung biopsies and a subset of both show patterns that would qualify as GLILD, while other cases lack granulomas but have identical patterns of lymphoid infiltration and organizing pneumonia. We suggest that GLILD is neither a specific nor a useful entity, and biopsies from CVID and IgAD patients should be diagnosed simply by microscopic pattern(s) observed. The prognosis of CVID with lymphoid infiltrates with or without granulomas in this series was good, contrary to claims in the literature about GLILD.
Achieving Congruence among Reference Laboratories for Absolute Abundance Measurement of Analytes for Rare Diseases: Psychosine for Diagnosis and Prognosis of Krabbe Disease
Herbst, Zackary M. , Turgeon, Coleman , Biski, Chad K. , Shoemaker, Nancy B., DeArmond, Patrick D. , Smith, Sara , Orsini, Joseph J. , Matern, Dietrich , Gelb, Michael H. , Turgeon, Coleman T, Khaledi, Hamid

Mayo Clinic

International Journal of Neonatal Screening | March 31, 2020 | Volume: 6 | Issue: 2 | Pages: 29

10.3390/ijns6020029 | PMID 32373753 Get It

Measurement of the absolute concentration of the biomarker psychosine in dried blood spots (DBS) is useful for diagnosis and prognosis of Krabbe disease and to support newborn screening of this leukodystrophy. As for assays for more common diseases, it is important to achieve congruence when multiple clinical laboratories provide testing. Four clinical laboratories, one research laboratory, and a commercial vendor collaborated with the goal to achieve congruence in quantitative psychosine measurement in DBS. A set of DBS calibrators was prepared by a single vendor and used in each reference laboratory to make a standard curve of measured psychosine in DBS versus the stated calibrator psychosine level. Congruence between the participating five laboratories was achieved using the psychosine DBS calibrators. This allowed application of disease-specific reference ranges obtained by the reference laboratory with the most extensive data by the other reference laboratories. Congruence between multiple reference laboratories in the measurement of the absolute concentration of biomarkers in DBS (and by extension other samples) is possible by the use of a common set of DBS calibrators.
Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of Diagnostic Testing for SARS–CoV-2/COVID-19
Patel, Robin , Babady, Esther , Theel, Elitza S. , Storch, Gregory A. , Pinsky, Benjamin A. , George, Kirsten St. , Smith, Tara C. , Bertuzzi, Stefano , Babady, N. Esther , St George, Kirsten , Patel, Robin , Pinsky, Benjamin A

Mayo Clinic

mBio | March 30, 2020 | Volume: 11 | Issue: 2 | Pages: No page available

10.1128/mbio.00722-20 | PMID 32217609 Get It

Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial
Newitt, David C. , Gibbs, Jessica , Wilmes, Lisa J., Jones, Ella F. , Joe, Bonnie N. , Sit, Laura , Chien, A. Jo , Price, Elissa R. , Albain, Kathy S. , Kuritza, Theresa , Morley, Kevin , Brandt, Kathy R., Choudhery, Sadia, Clark, Amy S. , Rosen, Mark, Wolverton, Dulcy , Fountain, Kelly , Euhus, David , Han, Heather, Niell, Bethany L. , Drukteinis, Jennifer S. , Lu, Janice , Mitri, Zaha, Nanda, Rita , Northfelt, Donald W. , Sanft, Tara, Stringer-Reasor, Erica , Viscusi, Rebecca K., Yung, Rachel L. , Asare, Smita , Melisko, Michelle , Perlmutter, Jane , Schwab, Richard B. , Veer, Laura J. van’t , Berry, Donald A. , Abé, Hiroyuki , Sheth, Deepa , Edmiston, Kirsten K., Ellis, Erin D. , Ha, Richard , Wynn, Ralph, Crane, Erin P., Dillis, Charlotte, Nelson, Michael T. , Church, An , Khan, Qamar J. , Oh, Karen Y. , Jafarian, Neda, Bang, Dae Hee , Mullins, Christiane, Woodard, Stefanie , Ojeda-Fornier, Haydee, Sheth, Pulin , Hovanessian‐Larsen, Linda , Eghtedari, Mohammad , Spektor, Michael , Giurescu, Marina E., Newell, Mary S. , Cohen, Michael A. , Berman, Elise, Smith, William P. , Fitzpatrick, Kim, Borders, Marisa H. , Yang, Wei , Goudreau, Sally , Brown, Thelma, Li, Wen , Onishi, Natsuko , Yau, Christina , Boughey, Judy C. , McDonald, Elizabeth S. , Elias, Anthony , Lang, Julie E. , Meisel, Jane Lowe , Sanft, Tara , Wallace, Anne M. , Yee, Douglas , Rugo, Hope S. , Symmans, W. Fraser , DeMichele, Angela , Isaacs, Claudine , Zamora, Kathryn , Lehman, Constance Dobbins , Dogan, Basak E , Esserman, Laura J. , Hylton, Nola M.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: PD9-04-PD9-04

10.1158/1538-7445.sabcs19-pd9-04 Get It

Abstract Background: In an adaptive randomized trial, when new treatment combinations are being tested, it is important to be able to identify patients who are progressing on treatment so that they can be changed to a different therapeutic regimen. We know that even within the molecularly high risk patients in I-SPY 2, there is considerable variation in biology. In this study, we will present results of using MRI-calculated functional tumor volume (FTV) to identify tumor progression for each breast cancer subtype. Methods: Patients (n=990) enrolled in the I-SPY 2 TRIAL who were randomized to the graduated experimental drug arms or controls from 2010 to 2016 were analyzed. Four MRI exams were performed for each patient: pre-NAC (T0), after 3 weeks of NAC (T1), between regimens (T2), and post-NAC (T3). Functional tumor volume (FTV) was calculated at each exam by summing voxels meeting enhancement thresholds. Tumor progression at T1, T2 or T3 was identified by a positive FTV change relative to T0. Visual inspection was used to exclude false progression due to strong background parenchymal enhancement post-contrast, prominent vessels, motion, or insufficient image quality. pCR was defined as no invasive disease in the breast and lymph nodes. Negative predictive value for pCR was defined as:NPV=number of true non-pCRs / number of patients with MRI assessed tumor progressions, where “true non-pCRs” referred to patients who were non-pCRs at surgery and were assessed as progressors by MRI. The analysis was performed in the full cohort and in sub-cohorts defined by HR and HER2 statuses. Results: Out of 990 patients, 878 had pCR outcome data (pCR or non-pCR, pCR rate = 35%). Total and non-pCR numbers for each subtype, number of patients with tumor progression assessed by MRI at T1, T2, and T3, and NPVs, are shown in Table 1. In the full cohort, the NPV increased consistently over treatment, from T1 (NPV=83%) to T2 (93%), and to T3 (100%). The HER2+ cancer subtypes showed fewer MRI-assessed tumor progressions than HER2- subtypes: e.g. 10/209 (5%) vs. 108/669 (16%) at T1. NPV was 100% for HER2+ subtypes at T1 and T2 except for a single misclassification of a HR- tumor at T1. Only 6 tumor progressors, all HER2- were identified at T3, and all were confirmed at surgery as non-pCRs (NPV=100%). For HR+/HER2-, the NPV increased slightly from 89% at T1 to 91% at T2, while triple negative subtype had a more substantial increase, from 78% to 92%. Conclusions: Our study showed strong association between tumor progressors assessed by MRI with true non-pCRs after NAC. For HER2+ tumors, although MRI progressors are rare, they strongly indicate non-pCR at all treatment time points, while HER2- subtypes show more accurate results later in treatment. We are evaluating MRI change at 6 weeks to determine if that time point is sufficient to predict progressors. Table 1 MRI assessed tumor progression at different treatment time pointN/non-pCRs/%non-pCRMRI assessed tumor progressionT1 (after 3 weeks)T2 (inter-regimen)T3 (post-NAC)NNPV (%)NNPV (%)NNPV (%)Full cohort878/572/65%11883.14192.76100%HR+/HER2-344/280/81%4588.91190.93100%HR+/HER2+134/85/63%610021000N/AHR-/HER2+75/23/31%47521000N/Atriple negative325/184/57%6377.82692.33100% Citation Format: Wen Li, Natsuko Onishi, David C Newitt, Jessica Gibbs, Lisa J Wilmes, Ella F Jones, Bonnie N Joe, Laura S Sit, Christina Yau, A. Jo Chien, Elissa Price, Kathy S Albain, Theresa Kuritza, Kevin Morley, Judy C Boughey, Kathy Brandt, Sadia Choudhery, Amy S Clark, Mark Rosen, Elizabeth S McDonald, Anthony D Elias, Dulcy Wolverton, Kelly Fountain, David M Euhus, Heather S Han, Bethany Niell, Jennifer Drukteinis, Julie E Lang, Janice Lu, Jane L Meisel, Zaha Mitri, Rita Nanda, Donald W Northfelt, Tara Sanft, Erica Stringer-Reasor, Rebecca K Viscusi, Anne M Wallace, Douglas Yee, Rachel Yung, Smita M Asare, Michelle E Melisko, Jane Perlmutter, Hope S Rugo, Richard Schwab, W. Fraser Symmans, Laura J van't Veer, Donald A Berry, Angela DeMichele, Hiroyuki Abe, Deepa Sheth, Kirsten K Edmiston, Erin D Ellis, Richard Ha, Ralph Wynn, Erin P Crane, Charlotte Dillis, Michael Nelson, An Church, Claudine Isaacs, Qamar J Khan, Karen Y Oh, Neda Jafarian, Dae Hee Bang, Christiane Mullins, Stefanie Woodard, Kathryn W Zamora, Haydee Ojeda-Fornier, Pulin Sheth, Linda Hovanessian-Larsen, Mohammad Eghtedari, Michael Spektor, Marina Giurescu, Mary S Newell, Michael A Cohen, Elise Berman, Constance Lehman, William Smith, Kim Fitzpatrick, Marisa H Borders, Wei Yang, Basak Dogan, Sally Goudreau, Thelma Brown, Laura J Esserman, Nola M Hylton. Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD9-04.
Abstract P6-08-04: Germline mutations in cancer predisposition genes in patients with invasive lobular carcinoma of the breast
LaDuca, Holly , Smith, Brandon , Goldgar, David E. , Pesaran, Tina , Dolinsky, Jill S. , Yadav, Siddhartha , Polley, Eric C. , Hu, Chunling , Hart, Steven N. , Na, Jie , Gnanaolivu, Rohan , Couch, Fergus J.

Mayo Clinic

Cancer Research | March 26, 2020 | Volume: 80 | Issue: 4_Supplement | Pages: P6-08-04-P6-08-04

10.1158/1538-7445.sabcs19-p6-08-04 Get It

Abstract Background: Invasive lobular carcinoma (ILC) of the breast accounts for approximately 10-15% of all histologic subtypes of breast cancer. However, apart from germline mutations in CDH1, the contributions of mutations in other cancer predisposition genes to ILC are largely unknown. Methods: The study population included 3,893 women with ILC of the breast who underwent germline multigene panel testing of cancer predisposition genes at Ambry Genetics from March 2012 to December 2016. The prevalence of predisposition gene mutations in women with ILC was assessed relative to 38,004 women with invasive ductal carcinoma (IDC) who underwent germline multigene panel testing at Ambry Genetics during the same timeframe. Associations between mutations in each gene and risk of ILC were evaluated using reference controls. Results: Of the 3,893 women with ILC included in this study, 70.7% were non-Hispanic white, 65.1% had a family history of breast cancer, and 96.4% had estrogen receptor (ER) positive breast cancer. The overall frequency of germline mutations in cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, MLH1, MRE11A, MSH2, MSH6, NBN, NF1, PALB2, PTEN, RAD51C, RAD51D and TP53) was 7.8% for women with ILC and 10.7% for women with IDC. Mutations in CDH1 were significantly more frequent (Odds Ratio (OR)=12.1, p&lt;0.001), whereas mutations in BRCA1 (OR=0.1; p&lt;0.001) and PALB2 (OR=0.4; p&lt;0.001)were less frequent in women with ILC, compared to women with IDC. When restricting the analysis to ER positive cases only, significant differences in frequencies of ATM (OR=0.6, p=0.03), BRCA1 (OR=0.3, p&lt;0.001), CDH1 (OR=7.7, p&lt;0.001) and PALB2 (OR=0.3, p&lt;0.001) were observed in ILC compared to IDC. By comparison with gnomAD reference controls, ATM, BRCA2, CDH1, CHEK2, PALB2 and PTEN mutations were significantly associated with an increased risk of lLC and IDC (OR&gt;2), NBN mutations were associated with ILC (OR=3.4; p&lt;0.001) but not IDC, and BRCA1 mutations were not associated with increased risk of ILC. Among 274 women with ILC over the age of 50 without history of any other cancer or a family history of breast or ovarian cancer, 14 (5.1%) were found to carry a mutation in one of the genes evaluated. Conclusions: In a large cohort of patients with ILC, the frequencies of germline mutations in cancer predisposition genes were similar between ILC and IDC except for ATM, BRCA1, CDH1 and PALB2. Six genes, in addition to CDH1, were found to be germline predisposition genes for ILC. A substantial proportion of patients older than 50 with ILC without a family history of breast or ovarian cancer or a personal history of other cancers were found to be mutation carriers. These findings improve our understanding of germline genetic drivers of ILC and suggest that multigene genetic testing should be considered for all ILC patients. Citation Format: Siddhartha Yadav, Holly LaDuca, Eric C. Polley, Chunling Hu, Steven N. Hart, Jie Na, Rohan Gnanaolivu, Brandon Smith, David E Goldgar, Tina Pesaran, Jill S. Dolinsky, Fergus J. Couch. Germline mutations in cancer predisposition genes in patients with invasive lobular carcinoma of the breast [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-08-04.